Company: ENTXW
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001178913-25-001674
Chunk: 4

Company: Entera Bio Ltd.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 31,

                        December 31,

                      Accrued expenses and other payables:

                        2025

                        2024

                      Employees and employees related

                      191

                      161

                      Provision for vacation

                      193

                      178

                      Accrued expenses

                      641

                      535

                      Other payables

                        295

                        -

                        1,320

                        874

12ENTERA BIO LTD.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except share and per share data)(Unaudited) 

          NOTE 5 - COLLABORATION AND RESEARCH AGREEMENTS

                a.
                
                  In April 2024, the Company entered into a material transfer and research project agreement (the “research services agreement”) with a third party. According to the agreement, the third party will pay the Company a monthly payment for the research services, as well as reimbursement for external expenses based on an agreed budget.

             The Company recognizes revenues according to ASC 606, "Revenues from Contracts with Customers”.

          The Company concluded that, because the research services provided under the research services agreement have no alternative use (because, in nature, these services are unique to each customer), and the Company has the right to receive payment for performance completed to date, the Company recognizes revenue over the contract term using the input model method.
           
          Revenues attributed to the research services agreement are recognized over the duration of the research services agreement.
           
          For the three months ended March 31, 2025, the Company recognized total revenues of $42 from this agreement.

                b.
                
                  On March 16, 2025, the Company entered into the 2025 Collaboration Agreement with OPKO and its wholly owned subsidiary, OPKO Biologics Ltd., to collaborate with respect to the preclinical and clinical development and decision making related to the oral delivery of a dual agonist GLP-1/glucagon peptide in an oral dosage form using Entera’s N-Tab™ technology platform for the treatment of obesity, metabolic and fibrotic disorders in humans (the “Program”). The Program combines OPKO’s proprietary long-acting oxyntomodulin (OXM, dual targeted GLP-1/Glucagon agonist, OPK-88006) analog and Entera’s proprietary N-Tab™ technology.

          Under the 2025 Collaboration Agreement, the